These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Current guidelines for the treatment of intra-abdominal infections]. Esposito S; Carosi G; Leone S Infez Med; 2008 Feb; 16 Suppl 1():46-52. PubMed ID: 18382150 [TBL] [Abstract][Full Text] [Related]
4. Cost of care and antibiotic prescribing attitudes for community-acquired complicated intra-abdominal infections in Italy: a retrospective study. Dalfino L; Bruno F; Colizza S; Concia E; Novelli A; Rebecchi F; Spandonaro F; Alato C World J Emerg Surg; 2014; 9():39. PubMed ID: 25028594 [TBL] [Abstract][Full Text] [Related]
5. [Evidence-based medicine, health costs and treatment of intra-abdominal infection]. Badía X; Brosa M; Tellado JM Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():86-94. PubMed ID: 10605193 [TBL] [Abstract][Full Text] [Related]
6. Economic impact simulation analysis of use of tigecycline, as appropriate, in first-course antibiotic therapy for complicated intra-abdominal infections in intensive care patients. Ancona F Minerva Med; 2010 Oct; 101(5):319-28. PubMed ID: 21048554 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK. Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194 [TBL] [Abstract][Full Text] [Related]
8. [Principles and application protocols in the treatment of intra-abdominal infections]. Concia E; Viscoli C Infez Med; 2008 Feb; 16 Suppl 1():57-62. PubMed ID: 18382152 [TBL] [Abstract][Full Text] [Related]
9. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Mallick R; Sun S; Schell SR Surg Infect (Larchmt); 2007 Apr; 8(2):159-72. PubMed ID: 17437361 [TBL] [Abstract][Full Text] [Related]
10. Clinical and economic consequences of failure of initial antibiotic therapy for patients with community-onset complicated intra-abdominal infections. Chong YP; Bae IG; Lee SR; Chung JW; Jun JB; Choo EJ; Moon SY; Lee MS; Jeon MH; Song EH; Lee EJ; Park SY; Kim YS PLoS One; 2015; 10(4):e0119956. PubMed ID: 25910171 [TBL] [Abstract][Full Text] [Related]
11. Importance of nondrug costs of intravenous antibiotic therapy. van Zanten AR; Engelfriet PM; van Dillen K; van Veen M; Nuijten MJ; Polderman KH Crit Care; 2003 Dec; 7(6):R184-90. PubMed ID: 14624694 [TBL] [Abstract][Full Text] [Related]
12. Reducing the costs of paediatric antibiotic prescribing in the community by implementing guideline recommendations. Piovani D; Clavenna A; Sequi M; Cartabia M; Bortolotti A; Fortino I; Merlino L; Bonati M; J Clin Pharm Ther; 2013 Oct; 38(5):373-8. PubMed ID: 23611435 [TBL] [Abstract][Full Text] [Related]
13. [New options for treatment of intraabdominal infections: tigecycline]. Menichetti F Infez Med; 2008 Feb; 16 Suppl 1():53-6. PubMed ID: 18382151 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. Eckmann C; Montravers P; Bassetti M; Bodmann KF; Heizmann WR; Sánchez García M; Guirao X; Capparella MR; Simoneau D; Dupont H J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii25-35. PubMed ID: 23772043 [TBL] [Abstract][Full Text] [Related]
15. [Assessment of tigecycline use economic impact in first-line therapy for complicated intra-abdominal infections in an Intensive Care Unit]. Ancona F Minerva Med; 2010 Aug; 101(4):195-204. PubMed ID: 21030933 [TBL] [Abstract][Full Text] [Related]
17. Antimicrobial consumption, costs and resistance patterns: a two year prospective study in a Romanian intensive care unit. Axente C; Licker M; Moldovan R; Hogea E; Muntean D; Horhat F; Bedreag O; Sandesc D; Papurica M; Dugaesescu D; Voicu M; Baditoiu L BMC Infect Dis; 2017 May; 17(1):358. PubMed ID: 28532467 [TBL] [Abstract][Full Text] [Related]
18. Rational use of antibiotics in the intensive care unit: impact on microbial resistance and costs. Geissler A; Gerbeaux P; Granier I; Blanc P; Facon K; Durand-Gasselin J Intensive Care Med; 2003 Jan; 29(1):49-54. PubMed ID: 12528022 [TBL] [Abstract][Full Text] [Related]
19. Excess annual economic burdens from nosocomial infections caused by multi-drug resistant bacteria in Thailand. Phodha T; Riewpaiboon A; Malathum K; Coyte PC Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):305-312. PubMed ID: 30321493 [TBL] [Abstract][Full Text] [Related]
20. Economic burden of antibiotic treatment of healthcare-associated infections at a tertiary care hospital ICU in Goa, India. Misal DD; Maulingkar SV; Bhonsle S Trop Doct; 2017 Jul; 47(3):197-201. PubMed ID: 27307475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]